IL17A and psoriasis: Importantly, IL-17- and IL-22-producing cells were strongly reduced by JAK blockade in IMQ-treated skin, similarly to what observed in human psoriasis, where improvement of clinical and histologic signs by tofacitinib was associated with an inhibition of IL-17 gene expression and IL-23/Th17 pathway [24].